New insights into the role of mitochondrial dysfunction and protein aggregation in Parkinson's disease

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1802, Issue 11, 2010, Pages 935-941

  Xie, Weilin ^a   Wan, Oi Wan ^a   Chung, Kenny K K ^a  

^a HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

Author keywords

Autophagy lysosomal pathway; Neurodegeneration; Parkin; PINK1; Ubiquitin proteasomal system

Indexed keywords

ALPHA SYNUCLEIN; PARKIN;

BRAIN MITOCHONDRION; DOPAMINERGIC NERVE CELL; HUMAN; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; REVIEW; SUBSTANTIA NIGRA;

EID: 77956699395     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2010.07.014     Document Type: Review

References (93)

1. Savitt J.M., Dawson V.L., Dawson T.M. Diagnosis and treatment of Parkinson disease: molecules to medicine. J. Clin. Invest. 2006, 116:1744-1754.
2. Tsang A.H., Chung K.K. Oxidative and nitrosative stress in Parkinson's disease. Biochim. Biophys. Acta 2009, 1792:643-650.
3. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39:889-909.
4. Thomas B., Beal M.F. Parkinson's disease. Hum. Mol. Genet. 2007, 16(Spec No. 2):R183-194.
5. Satake W., Nakabayashi Y., Mizuta I., Hirota Y., Ito C., Kubo M., Kawaguchi T., Tsunoda T., Watanabe M., Takeda A., Tomiyama H., Nakashima K., Hasegawa K., Obata F., Yoshikawa T., Kawakami H., Sakoda S., Yamamoto M., Hattori N., Murata M., Nakamura Y., Toda T. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat. Genet. 2009, 41:1303-1307.
6. Simon-Sanchez J., Schulte C., Bras J.M., Sharma M., Gibbs J.R., Berg D., Paisan-Ruiz C., Lichtner P., Scholz S.W., Hernandez D.G., Kruger R., Federoff M., Klein C., Goate A., Perlmutter J., Bonin M., Nalls M.A., Illig T., Gieger C., Houlden H., Steffens M., Okun M.S., Racette B.A., Cookson M.R., Foote K.D., Fernandez H.H., Traynor B.J., Schreiber S., Arepalli S., Zonozi R., Gwinn K., van der Brug M., Lopez G., Chanock S.J., Schatzkin A., Park Y., Hollenbeck A., Gao J., Huang X., Wood N.W., Lorenz D., Deuschl G., Chen H., Riess O., Hardy J.A., Singleton A.B., Gasser T. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat. Genet. 2009, 41:1308-1312.
7. Thomas B. Parkinson's disease: from molecular pathways in disease to therapeutic approaches. Antioxid. Redox Signal. 2009, 11:2077-2082.
8. Spillantini M.G., Crowther R.A., Jakes R., Hasegawa M., Goedert M. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:6469-6473.
9. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997, 388:839-840.
10. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., Przuntek H., Epplen J.T., Schols L., Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 1998, 18:106-108.
11. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997, 276:2045-2047.
12. Singleton A.B., Farrer M., Johnson J., Singleton A., Hague S., Kachergus J., Hulihan M., Peuralinna T., Dutra A., Nussbaum R., Lincoln S., Crawley A., Hanson M., Maraganore D., Adler C., Cookson M.R., Muenter M., Baptista M., Miller D., Blancato J., Hardy J., Gwinn-Hardy K. alpha-Synuclein locus triplication causes Parkinson's disease. Science 2003, 302:841.
13. Zarranz J.J., Alegre J., Gomez-Esteban J.C., Lezcano E., Ros R., Ampuero I., Vidal L., Hoenicka J., Rodriguez O., Atares B., Llorens V., Gomez Tortosa E., del Ser T., Munoz D.G., de Yebenes J.G. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 2004, 55:164-173.
14. Nakamura K., Nemani V.M., Wallender E.K., Kaehlcke K., Ott M., Edwards R.H. Optical reporters for the conformation of alpha-synuclein reveal a specific interaction with mitochondria. J. Neurosci. 2008, 28:12305-12317.
15. Parihar M.S., Parihar A., Fujita M., Hashimoto M., Ghafourifar P. Mitochondrial association of alpha-synuclein causes oxidative stress. Cell. Mol. Life Sci. 2008, 65:1272-1284.
16. Conway K.A., Harper J.D., Lansbury P.T. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry 2000, 39:2552-2563.
17. Conway K.A., Lee S.J., Rochet J.C., Ding T.T., Williamson R.E., Lansbury P.T. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:571-576.
18. Fredenburg R.A., Rospigliosi C., Meray R.K., Kessler J.C., Lashuel H.A., Eliezer D., Lansbury P.T. The impact of the E46K mutation on the properties of alpha-synuclein in its monomeric and oligomeric states. Biochemistry 2007, 46:7107-7118.
19. Kim H.Y., Cho M.K., Kumar A., Maier E., Siebenhaar C., Becker S., Fernandez C.O., Lashuel H.A., Benz R., Lange A., Zweckstetter M. Structural properties of pore-forming oligomers of alpha-synuclein. J. Am. Chem. Soc. 2009, 131:17482-17489.
20. Lashuel H.A., Hartley D., Petre B.M., Walz T., Lansbury P.T. Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 2002, 418:291.
21. Devi L., Raghavendran V., Prabhu B.M., Avadhani N.G., Anandatheerthavarada H.K. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J. Biol. Chem. 2008, 283:9089-9100.
22. Martin L.J., Pan Y., Price A.C., Sterling W., Copeland N.G., Jenkins N.A., Price D.L., Lee M.K. Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J. Neurosci. 2006, 26:41-50.
23. Dauer W., Kholodilov N., Vila M., Trillat A.C., Goodchild R., Larsen K.E., Staal R., Tieu K., Schmitz Y., Yuan C.A., Rocha M., Jackson-Lewis V., Hersch S., Sulzer D., Przedborski S., Burke R., Hen R. Resistance of alpha-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:14524-14529.
24. Klivenyi P., Siwek D., Gardian G., Yang L., Starkov A., Cleren C., Ferrante R.J., Kowall N.W., Abeliovich A., Beal M.F. Mice lacking alpha-synuclein are resistant to mitochondrial toxins. Neurobiol. Dis. 2006, 21:541-548.
25. Chandra S., Gallardo G., Fernandez-Chacon R., Schluter O.M., Sudhof T.C. Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell 2005, 123:383-396.
26. Valente E.M., Abou-Sleiman P.M., Caputo V., Muqit M.M., Harvey K., Gispert S., Ali Z., Del Turco D., Bentivoglio A.R., Healy D.G., Albanese A., Nussbaum R., Gonzalez-Maldonado R., Deller T., Salvi S., Cortelli P., Gilks W.P., Latchman D.S., Harvey R.J., Dallapiccola B., Auburger G., Wood N.W. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 2004, 304:1158-1160.
27. Silvestri L., Caputo V., Bellacchio E., Atorino L., Dallapiccola B., Valente E.M., Casari G. Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism. Hum. Mol. Genet. 2005, 14:3477-3492.
28. Gandhi S., Muqit M.M., Stanyer L., Healy D.G., Abou-Sleiman P.M., Hargreaves I., Heales S., Ganguly M., Parsons L., Lees A.J., Latchman D.S., Holton J.L., Wood N.W., Revesz T. PINK1 protein in normal human brain and Parkinson's disease. Brain 2006, 129:1720-1731.
29. Beilina A., Van Der Brug M., Ahmad R., Kesavapany S., Miller D.W., Petsko G.A., Cookson M.R. Mutations in PTEN-induced putative kinase 1 associated with recessive parkinsonism have differential effects on protein stability. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:5703-5708.
30. Weihofen A., Ostaszewski B., Minami Y., Selkoe D.J. Pink1 Parkinson mutations, the Cdc37/Hsp90 chaperones and Parkin all influence the maturation or subcellular distribution of Pink1. Hum. Mol. Genet. 2008, 17:602-616.
31. Petit A., Kawarai T., Paitel E., Sanjo N., Maj M., Scheid M., Chen F., Gu Y., Hasegawa H., Salehi-Rad S., Wang L., Rogaeva E., Fraser P., Robinson B., St George-Hyslop P., Tandon A. Wild-type PINK1 prevents basal and induced neuronal apoptosis, a protective effect abrogated by Parkinson disease-related mutations. J. Biol. Chem. 2005, 280:34025-34032.
32. Exner N., Treske B., Paquet D., Holmstrom K., Schiesling C., Gispert S., Carballo-Carbajal I., Berg D., Hoepken H.H., Gasser T., Kruger R., Winklhofer K.F., Vogel F., Reichert A.S., Auburger G., Kahle P.J., Schmid B., Haass C. Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin. J. Neurosci. 2007, 27:12413-12418.
33. Wood-Kaczmar A., Gandhi S., Yao Z., Abramov A.Y., Miljan E.A., Keen G., Stanyer L., Hargreaves I., Klupsch K., Deas E., Downward J., Mansfield L., Jat P., Taylor J., Heales S., Duchen M.R., Latchman D., Tabrizi S.J., Wood N.W. PINK1 is necessary for long term survival and mitochondrial function in human dopaminergic neurons. PLoS One 2008, 3:e2455.
34. Clark I.E., Dodson M.W., Jiang C., Cao J.H., Huh J.R., Seol J.H., Yoo S.J., Hay B.A., Guo M. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 2006, 441:1162-1166.
35. Park J., Lee S.B., Lee S., Kim Y., Song S., Kim S., Bae E., Kim J., Shong M., Kim J.M., Chung J. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 2006, 441:1157-1161.
36. Yang Y., Gehrke S., Imai Y., Huang Z., Ouyang Y., Wang J.W., Yang L., Beal M.F., Vogel H., Lu B. Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:10793-10798.
37. Plun-Favreau H., Klupsch K., Moisoi N., Gandhi S., Kjaer S., Frith D., Harvey K., Deas E., Harvey R.J., McDonald N., Wood N.W., Martins L.M., Downward J. The mitochondrial protease HtrA2 is regulated by Parkinson's disease-associated kinase PINK1. Nat. Cell Biol. 2007, 9:1243-1252.
38. Pridgeon J.W., Olzmann J.A., Chin L.S., Li L. PINK1 protects against oxidative stress by phosphorylating mitochondrial chaperone TRAP1. PLoS Biol. 2007, 5:e172.
39. Jones J.M., Datta P., Srinivasula S.M., Ji W., Gupta S., Zhang Z., Davies E., Hajnoczky G., Saunders T.L., Van Keuren M.L., Fernandes-Alnemri T., Meisler M.H., Alnemri E.S. Loss of Omi mitochondrial protease activity causes the neuromuscular disorder of mnd2 mutant mice. Nature 2003, 425:721-727.
40. Strauss K.M., Martins L.M., Plun-Favreau H., Marx F.P., Kautzmann S., Berg D., Gasser T., Wszolek Z., Muller T., Bornemann A., Wolburg H., Downward J., Riess O., Schulz J.B., Kruger R. Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. Hum. Mol. Genet. 2005, 14:2099-2111.
41. R. Kruger, M. Sharma, O. Riess, T. Gasser, C. Van Broeckhoven, J. Theuns, J. Aasly, G. Annesi, A.R. Bentivoglio, A. Brice, A. Djarmati, A. Elbaz, M. Farrer, C. Ferrarese, J.M. Gibson, G.M. Hadjigeorgiou, N. Hattori, J.P. Ioannidis, B. Jasinska-Myga, C. Klein, J.C. Lambert, S. Lesage, J.J. Lin, T. Lynch, G.D. Mellick, F. de Nigris, G. Opala, A. Prigione, A. Quattrone, O.A. Ross, W. Satake, P.A. Silburn, E.K. Tan, T. Toda, H. Tomiyama, K. Wirdefeldt, Z. Wszolek, G. Xiromerisiou, D.M. Maraganore, A large-scale genetic association study to evaluate the contribution of Omi/HtrA2 (PARK13) to Parkinson's disease, Neurobiol. Aging (in press). doi:10.1016/j.neurobiolaging.2009.11.021.
42. Deng H., Dodson M.W., Huang H., Guo M. The Parkinson's disease genes pink1 and parkin promote mitochondrial fission and/or inhibit fusion in Drosophila. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:14503-14508.
43. Poole A.C., Thomas R.E., Andrews L.A., McBride H.M., Whitworth A.J., Pallanck L.J. The PINK1/Parkin pathway regulates mitochondrial morphology. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:1638-1643.
44. Vives-Bauza C., Zhou C., Huang Y., Cui M., de Vries R.L., Kim J., May J., Tocilescu M.A., Liu W., Ko H.S., Magrane J., Moore D.J., Dawson V.L., Grailhe R., Dawson T.M., Li C., Tieu K., Przedborski S. PINK1-dependent recruitment of Parkin to mitochondria in mitophagy. Proc. Natl. Acad. Sci. U. S. A. 2009, 107:378-383.
45. Geisler S., Holmstrom K.M., Skujat D., Fiesel F.C., Rothfuss O.C., Kahle P.J., Springer W. PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nat. Cell Biol. 2010, 12:119-131.
46. Ziviani E., Tao R.N., Whitworth A.J. Drosophila Parkin requires PINK1 for mitochondrial translocation and ubiquitinates Mitofusin. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:5018-5023.
47. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., Yokochi M., Mizuno Y., Shimizu N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998, 392:605-608.
48. Shimura H., Hattori N., Kubo S., Mizuno Y., Asakawa S., Minoshima S., Shimizu N., Iwai K., Chiba T., Tanaka K., Suzuki T. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat. Genet. 2000, 25:302-305.
49. Zhang Y., Gao J., Chung K.K., Huang H., Dawson V.L., Dawson T.M. Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:13354-13359.
50. Dawson T.M., Dawson V.L. Molecular pathways of neurodegeneration in Parkinson's disease. Science 2003, 302:819-822.
51. Takahashi T., Yamashita H., Nakamura T., Nagano Y., Nakamura S. Tyrosine 125 of alpha-synuclein plays a critical role for dimerization following nitrative stress. Brain Res. 2002, 938:73-80.
52. Mazzulli J.R., Mishizen A.J., Giasson B.I., Lynch D.R., Thomas S.A., Nakashima A., Nagatsu T., Ota A., Ischiropoulos H. Cytosolic catechols inhibit alpha-synuclein aggregation and facilitate the formation of intracellular soluble oligomeric intermediates. J. Neurosci. 2006, 26:10068-10078.
53. Norris E.H., Giasson B.I., Hodara R., Xu S., Trojanowski J.Q., Ischiropoulos H., Lee V.M. Reversible inhibition of alpha-synuclein fibrillization by dopaminochrome-mediated conformational alterations. J. Biol. Chem. 2005, 280:21212-21219.
54. Mosharov E.V., Staal R.G., Bove J., Prou D., Hananiya A., Markov D., Poulsen N., Larsen K.E., Moore C.M., Troyer M.D., Edwards R.H., Przedborski S., Sulzer D. Alpha-synuclein overexpression increases cytosolic catecholamine concentration. J. Neurosci. 2006, 26:9304-9311.
55. Volles M.J., Lansbury P.T. Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. Biochemistry 2002, 41:4595-4602.
56. Fujiwara H., Hasegawa M., Dohmae N., Kawashima A., Masliah E., Goldberg M.S., Shen J., Takio K., Iwatsubo T. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 2002, 4:160-164.
57. Takahashi M., Kanuka H., Fujiwara H., Koyama A., Hasegawa M., Miura M., Iwatsubo T. Phosphorylation of alpha-synuclein characteristic of synucleinopathy lesions is recapitulated in alpha-synuclein transgenic Drosophila. Neurosci. Lett. 2003, 336:155-158.
58. Olanow C.W., Prusiner S.B. Is Parkinson's disease a prion disorder?. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:12571-12572.
59. Kordower J.H., Chu Y., Hauser R.A., Freeman T.B., Olanow C.W. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat. Med. 2008, 14:504-506.
60. Li J.Y., Englund E., Holton J.L., Soulet D., Hagell P., Lees A.J., Lashley T., Quinn N.P., Rehncrona S., Bjorklund A., Widner H., Revesz T., Lindvall O., Brundin P. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat. Med. 2008, 14:501-503.
61. Desplats P., Lee H.J., Bae E.J., Patrick C., Rockenstein E., Crews L., Spencer B., Masliah E., Lee S.J. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:13010-13015.
62. Bennett M.C., Bishop J.F., Leng Y., Chock P.B., Chase T.N., Mouradian M.M. Degradation of alpha-synuclein by proteasome. J. Biol. Chem. 1999, 274:33855-33858.
63. Tofaris G.K., Layfield R., Spillantini M.G. alpha-Synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome. FEBS Lett. 2001, 509:22-26.
64. Cuervo A.M., Stefanis L., Fredenburg R., Lansbury P.T., Sulzer D. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 2004, 305:1292-1295.
65. Martinez-Vicente M., Talloczy Z., Kaushik S., Massey A.C., Mazzulli J., Mosharov E.V., Hodara R., Fredenburg R., Wu D.C., Follenzi A., Dauer W., Przedborski S., Ischiropoulos H., Lansbury P.T., Sulzer D., Cuervo A.M. Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. J. Clin. Invest. 2008, 118:777-788.
66. Mak S.K., McCormack A.L., Manning-Bog A.B., Cuervo A.M., Di Monte D.A. Lysosomal degradation of {alpha}-synuclein in vivo. J. Biol. Chem. 2010, 285:13621-13629.
67. Shin J.H., Dawson V.L., Dawson T.M. SnapShot: pathogenesis of Parkinson's disease. Cell 2009, 139(440):e441-442.
68. Li S., Hong S., Shepardson N.E., Walsh D.M., Shankar G.M., Selkoe D. Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron 2009, 62:788-801.
69. Shankar G.M., Li S., Mehta T.H., Garcia-Munoz A., Shepardson N.E., Smith I., Brett F.M., Farrell M.A., Rowan M.J., Lemere C.A., Regan C.M., Walsh D.M., Sabatini B.L., Selkoe D.J. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 2008, 14:837-842.
70. Arrasate M., Mitra S., Schweitzer E.S., Segal M.R., Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 2004, 431:805-810.
71. Burke W.J., Kumar V.B., Pandey N., Panneton W.M., Gan Q., Franko M.W., O'Dell M., Li S.W., Pan Y., Chung H.D., Galvin J.E. Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine. Acta Neuropathol. 2008, 115:193-203.
72. Demuro A., Mina E., Kayed R., Milton S.C., Parker I., Glabe C.G. Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J. Biol. Chem. 2005, 280:17294-17300.
73. Lashuel H.A., Petre B.M., Wall J., Simon M., Nowak R.J., Walz T., Lansbury P.T. Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J. Mol. Biol. 2002, 322:1089-1102.
74. Liu G., Zhang C., Yin J., Li X., Cheng F., Li Y., Yang H., Uéda K., Chan P., Yu S. alpha-Synuclein is differentially expressed in mitochondria from different rat brain regions and dose-dependently down-regulates complex I activity. Neurosci. Lett. 2009, 454:187-192.
75. Loeb V., Yakunin E., Saada A., Sharon R. The transgenic over expression of alpha-Synuclein and not its related pathology associates with complex I inhibition. J. Biol. Chem. 2010, 285:7334-7343.
76. Snyder H., Mensah K., Theisler C., Lee J., Matouschek A., Wolozin B. Aggregated and monomeric alpha-synuclein bind to the S6' proteasomal protein and inhibit proteasomal function. J. Biol. Chem. 2003, 278:11753-11759.
77. Tanaka Y., Engelender S., Igarashi S., Rao R.K., Wanner T., Tanzi R.E., Sawa A., L.D.V., Dawson T.M., Ross C.A. Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum. Mol. Genet. 2001, 10:919-926.
78. Cooper A.A., Gitler A.D., Cashikar A., Haynes C.M., Hill K.J., Bhullar B., Liu K., Xu K., Strathearn K.E., Liu F., Cao S., Caldwell K.A., Caldwell G.A., Marsischky G., Kolodner R.D., Labaer J., Rochet J.C., Bonini N.M., Lindquist S. Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 2006, 313:324-328.
79. Gitler A.D., Bevis B.J., Shorter J., Strathearn K.E., Hamamichi S., Su L.J., Caldwell K.A., Caldwell G.A., Rochet J.C., McCaffery J.M., Barlowe C., Lindquist S. The Parkinson's disease protein alpha-synuclein disrupts cellular Rab homeostasis. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:145-150.
80. Thayanidhi N., Helm J.R., Nycz D.C., Bentley M., Liang Y., Hay J.C. Alpha-synuclein delays endoplasmic reticulum (ER)-to-Golgi transport in mammalian cells by antagonizing ER/Golgi SNAREs. Mol Biol Cell 2010, 21:1850-1863.
81. Dawson T.M., Dawson V.L. The role of parkin in familial and sporadic Parkinson's disease. Mov. Disord. 2010, 25(Suppl 1):S32-39.
82. McNaught K.S., Belizaire R., Isacson O., Jenner P., Olanow C.W. Altered proteasomal function in sporadic Parkinson's disease. Exp. Neurol. 2003, 179:38-46.
83. Bove J., Zhou C., Jackson-Lewis V., Taylor J., Chu Y., Rideout H.J., Wu D.C., Kordower J.H., Petrucelli L., Przedborski S. Proteasome inhibition and Parkinson's disease modeling. Ann. Neurol. 2006, 60:260-264.
84. Kordower J.H., Kanaan N.M., Chu Y., Suresh Babu R., Stansell J., Terpstra B.T., Sortwell C.E., Steece-Collier K., Collier T.J. Failure of proteasome inhibitor administration to provide a model of Parkinson's disease in rats and monkeys. Ann. Neurol. 2006, 60:264-268.
85. Manning-Bog A.B., Reaney S.H., Chou V.P., Johnston L.C., McCormack A.L., Johnston J., Langston J.W., Di Monte D.A. Lack of nigrostriatal pathology in a rat model of proteasome inhibition. Ann. Neurol. 2006, 60:256-260.
86. McNaught K.S., Olanow C.W. Proteasome inhibitor-induced model of Parkinson's disease. Ann. Neurol. 2006, 60:243-247.
87. Beal F., Lang A. The proteasomal inhibition model of Parkinson's disease: "boon or bust"?. Ann. Neurol. 2006, 60:158-161.
88. Lee F.K., Wong A.K., Lee Y.W., Wan O.W., Chan H.Y., Chung K.K. The role of ubiquitin linkages on alpha-synuclein induced-toxicity in a Drosophila model of Parkinson's disease. J. Neurochem. 2009, 110:208-219.
89. Pan T., Kondo S., Le W., Jankovic J. The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease. Brain 2008, 131:1969-1978.
90. Rubinsztein D.C. The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 2006, 443:780-786.
91. Ramirez A., Heimbach A., Grundemann J., Stiller B., Hampshire D., Cid L.P., Goebel I., Mubaidin A.F., Wriekat A.L., Roeper J., Al-Din A., Hillmer A.M., Karsak M., Liss B., Woods C.G., Behrens M.I., Kubisch C. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat. Genet. 2006, 38:1184-1191.
92. Sidransky E., Nalls M.A., Aasly J.O., Aharon-Peretz J., Annesi G., Barbosa E.R., Bar-Shira A., Berg D., Bras J., Brice A., Chen C.M., Clark L.N., Condroyer C., De Marco E.V., Durr A., Eblan M.J., Fahn S., Farrer M.J., Fung H.C., Gan-Or Z., Gasser T., Gershoni-Baruch R., Giladi N., Griffith A., Gurevich T., Januario C., Kropp P., Lang A.E., Lee-Chen G.J., Lesage S., Marder K., Mata I.F., Mirelman A., Mitsui J., Mizuta I., Nicoletti G., Oliveira C., Ottman R., Orr-Urtreger A., Pereira L.V., Quattrone A., Rogaeva E., Rolfs A., Rosenbaum H., Rozenberg R., Samii A., Samaddar T., Schulte C., Sharma M., Singleton A., Spitz M., Tan E.K., Tayebi N., Toda T., Troiano A.R., Tsuji S., Wittstock M., Wolfsberg T.G., Wu Y.R., Zabetian C.P., Zhao Y., Ziegler S.G. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N. Engl. J. Med. 2009, 361:1651-1661.
93. Matsuda N., Tanaka K. Does impairment of the ubiquitin-proteasome system or the autophagy-lysosome pathway predispose individuals to neurodegenerative disorders such as Parkinson's disease?. J. Alzheimers Dis. 2009, 19:1-9.